Indian pharma firms seek Trump's appointment to trade low cost medicines against lower import tax

With speculations rife over Trump's health policies after repeal of Obamacare, India's big pharmaceutical firms have also set their eyes on the US policy reformation.  
 

In a bid to capitalise on Trump's promise to lower drug costs, Indian pharma firms are seeking the US President's appointment to convince him to outsource the manufacturing of drugs to the Indian firms. 

The Indian pharma industry is the world's biggest exporter of copycat medicines that are 80 per cent cheaper than the branded medicines. Trump's multifarious decrees over the healthcare policies pose big opportunities amidst the threats against the USD 12.5 billion Indian annual drug exports.       

The South Asian economies constitute 20 per cent of the total global generic drug exports, with Indian industry capitalising on its 50 per cent lower manufacturing cost in comparison with the other western countries.     
 

If Indian pharma companies find an exception to Trump's proclamation of supporting US manufacturing industry and boycotting imports along with the threat of tax imposition on imports, big Indian pharma firms like Sun Pharmaceutical, Dr. Reddy’s and Lupin Ltd will receive a major boost in their markets.